SK Biopharmaceuticals Co., Ltd

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.